Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | JIMT-1 is a human breast cancer cell line established in 2003 by M. Tanner and colleagues at the University of Tampere. This cell line was isolated from the pleural effusion of a 62-year-old female patient diagnosed with aggressive Grade 3 ductal breast carcinoma. During treatment with the anti-HER2 monoclonal antibody trastuzumab, the patient exhibited rapid clinical disease progression and developed drug resistance. The JIMT-1 cell line is widely recognized as the "gold standard" in vitro model for investigating the mechanisms of "intrinsic trastuzumab resistance" in HER2-positive breast cancer. Although this cell line is characterized by significant HER2 (ERBB2) gene amplification and overexpression of the HER2 receptor, the cells remain completely insensitive to trastuzumab due to the synergistic effects of receptor shedding mechanisms (mediated by MUC4 expression) and the activation of the downstream PIK3CA pathway. Consequently, it has become a critical tool for evaluating next-generation antibody-drug conjugates (ADCs) and combination targeted therapies. |
| Tissue | Breast; Mammary gland; derived from metastatic site (Pleural Effusion) |
| Disease | Breast Carcinoma (Ductal) |
| Morphology | Epithelial-like; polygonal cells growing as an adherent monolayer |
| Gender | Female |
| Age | 62 years |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. "Gold standard" models for elucidating the mechanisms of primary and acquired resistance to trastuzumab; 2. Preclinical evaluation of novel anti-HER2 antibody-drug conjugates; 3. Deciphering the mechanisms of crosstalk within the PI3K/Akt/mTOR signaling pathway in gene-amplified malignancies; 4. Investigating the role of steric hindrance by Mucin-4 (MUC4) in masking therapeutic antibody binding sites; 5. Establishment of human breast cancer xenograft models exhibiting drug resistance in immunodeficient mice. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C (Liquid nitrogen vapor phase) |
| Characteristics | |
| Tumorigenic | Yes, highly tumorigenic in immunocompromised mice (forms tumors that mimic clinical trastuzumab resistance) |
| Karyotype | The human karyotype is hypotetraploid, with a modal chromosome number centered at 81 (range: 73–86) and a <4n>XX constitution. Its characteristics include a large number of unclassifiable marker chromosomes and complex chromosomal rearrangements—features that are typical hallmarks of genomic instability in advanced breast cancer. |
| Genetic Profile | 1. HER2 (ERBB2) Status: Amplification at the genomic level; overexpression at the protein level. 2. PIK3CA Mutation Status: Harbors a hyperactivating hotspot mutation on Exon 7: p.Cys420Rgs (c.1258G>A). 3. TP53 Mutation Status: Mutated (harbors an altering mutation resulting in p53 dysregulation). 4. Hormone Receptor Status: Estrogen Receptor (ER) negative; Progesterone Receptor (PR) negative. |
| Resistance Mechanism | Expresses high levels of MUC4 (Mucin-4), which sterically blocks trastuzumab from binding to the HER2 extracellular domain, paired with concurrent downstream PIK3CA mutation-driven survival signaling. |
| Growth Kinetics | Moderate to rapid adherent monolayer expansion; typical doubling time spans 30 to 40 hours. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the spent culture medium from the culture flask. 2. Gently rinse the cell monolayer with Ca²⁺/Mg²⁺-free Dulbecco's Phosphate-Buffered Saline (DPBS) to neutralize any residual traces of serum containing trypsin inhibitors. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, ensuring the cell layer is completely submerged. 4. Incubate at 37°C for 3 to 7 minutes; observe closely under an inverted microscope until the cell layer has completely detached and the cells have rounded up. 5. Add an equal or greater volume of complete culture medium to the flask to thoroughly neutralize the trypsin activity. 6. Centrifuge at approximately 200-300 × g for 5 minutes; decant the supernatant, uniformly resuspend the cell pellet in fresh culture medium, and aliquot into new culture vessels. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A split ratio of 1:3 to 1:6 is standardly recommended for routine maintenance. |
| Culture Conditions | Atmosphere: Air, 100% (If using L-15 Medium) OR Air, 95%, CO2, 5% (If using DMEM); Temperature: 37°C |
| Cryopreservation | 90% Complete growth medium + 10% DMSO (or 50% Basal medium + 40% FBS + 10% DMSO) |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO01190 | Cas9 Stable Cell Line - JIMT-1 | Inquiry |
| CSC-RR00683 | Luciferase Reporter Cell Line - JIMT-1 | Inquiry |
| CSC-RO01607 | OVAL Stable Cell Line - JIMT-1 | Inquiry |
| CSC-RO01860 | GFP/OVAL Stable Cell Line - JIMT-1 | Inquiry |
| CSC-RO02113 | Luc/OVAL Stable Cell Line - JIMT-1 | Inquiry |
| CSC-RO02366 | GFP/Luc/OVAL Stable Cell Line - JIMT-1 | Inquiry |
| CSC-RR01008 | GFP/Luc Reporter Cell Line - JIMT-1 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.